April 27, 2022
US Oncology Research BioTech Day, Early Development Program Summit
Samuel Lam, PhD, Vice President of Science and Research at Immunophotonics, Inc. and Markus Joerger, MD, PhD, Clinical Trial Principal...
Read More
April 20, 2022
European Conference on Interventional Oncology (EICO 2022) April 24–27, 2022
Interested in learning how Immunophotonics, Inc. continues to explore the ability of IP-001 to transform a routine interventional-oncology procedure into...
Read More
April 13, 2022
Immunophotonics Announces Appointment of Miguel Zubizarreta to Its Board of Directors
Immunophotonics has strengthened its leadership with the appointment of Miguel Zubizarreta to its Board of Directors. Mr. Zubizarreta, a tech...
Read More
April 12, 2022
American Association for Cancer Research (AACR) Annual Meeting, April 8 – 13, 2022
Look for Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. in New Orleans at the American Association for...
Read More
April 6, 2022
Immunophotonics Raises $21.4 Million in Equity Financing for Phase 2 Clinical Trials
Immunophotonics continues to attract investments that will fund research and clinical trials regarding the use of the company’s lead drug...
Read More
March 31, 2021
Dr. Wei R. Chen Elected to the 2022 Class of the AIMBE College of Fellows
Lu Alleruzzo, CEO; Tomas Hode, CIO & President; and the Immunophotonics Team want to congratulate Dr. Wei Chen on being...
Read More
March 28, 2022
SIO Annual Scientific Meeting, March 24 -28, 2022
Tomas Hode, PhD, Co-Founder, CIO, and President at Immunophotonics, Inc. attended the SIO 2022 annual scientific meeting March 24 –...
Read More
March 11, 2022
2022 NYSE IPO Summit
Lu Alleruzzo co-founder and CEO of Immunophotonics attended the NYSE 9th Annual 2022 IPO Summit. Very inspiring to hear from...
Read More
March 4, 2022
2022 St. Louis Dealmaker of the Year
The continued success of Immunophotonics is driven by the dedication and hard work of our team. Immunophotonics was one of...
Read More
February 17, 2022
Immunophotonics Awarded $2.4 Million SBIR Grant by the National Cancer Institute
Immunophotonics, Inc. was recently awarded a Small Business Innovative Research (SBIR) Phase I and Phase II Fast-Track grant for research...
Read More